Core Viewpoint - Ventas (VTR) has experienced a significant stock price increase of 16.3% year-to-date, outperforming the industry growth of 4.4% [1][8] Company Overview - Ventas possesses a diverse portfolio of healthcare real estate assets in key markets in the U.S. and the U.K., positioning it to benefit from favorable industry fundamentals [2] - The senior housing operating portfolio (SHOP) is expected to gain from the aging population and increased healthcare spending by seniors [2] - The outpatient medical portfolio is anticipated to benefit from positive trends in outpatient visits [2] Financial Performance - The company has seen a 13.3% year-over-year growth in same-store cash NOI within the SHOP portfolio for Q2 2025 [5][8] - As of Q2 2025, Ventas reported liquidity of $4.7 billion, with net debt to EBITDA improving to 5.6X [8][10] - The Zacks Consensus Estimate for Ventas' 2025 FFO per share has been slightly revised upward to $3.46 over the past two months [3] Strategic Initiatives - Ventas is actively rebalancing its portfolio, which is expected to drive future revenue growth [3] - The company has expanded its operator base from 10 to 36 since December 2020, enhancing its growth potential in high-demand markets [5] - A disciplined capital-recycling strategy is in place, allowing the company to dispose of non-core assets and reinvest in premium acquisitions [9] Market Trends - The senior citizen population is projected to increase, providing a multi-year growth opportunity in senior housing [4] - The healthcare sector is relatively insulated from macroeconomic uncertainties, offering stability during economic downturns [4] - The growing population aged 65 and above is contributing to an increase in outpatient visits, which the outpatient medical and research (OM&R) portfolio is well-positioned to capitalize on [6]

Core Viewpoint - Ventas, Inc. (VTR) reported strong first-quarter 2025 results, with normalized funds from operations (FFO) per share of 84 cents, exceeding estimates and reflecting a 7.7% year-over-year increase [1][3] Financial Performance - VTR achieved revenues of $1.36 billion in Q1 2025, surpassing the Zacks Consensus Estimate of $1.30 billion and marking a 13.2% year-over-year growth [2] - Same-store cash net operating income (NOI) for the total property portfolio increased 7.1% to $485.4 million compared to the prior year [3] - The same-store cash NOI for the Senior Housing Operating Portfolio (SHOP) rose 13.6% year over year to $220.5 million, supported by a 3.8% growth in revenues per occupied room [4] Segment Performance - The outpatient medical and research portfolio's same-store cash NOI improved 1.3% year over year to $137.3 million, driven by higher average rent and revenue per occupied square foot [5] - The triple-net leased portfolio's same-store cash NOI increased 3.2% year over year to $127.6 million [5] Balance Sheet Position - At the end of Q1 2025, VTR had cash and cash equivalents of $182.3 million, down from $897.9 million at the end of 2024, with total liquidity of $2.9 billion [6] 2025 Guidance - VTR reaffirmed its 2025 normalized FFO per share guidance of $3.35-$3.46, with a midpoint of $3.41, and expects total same-store cash NOI growth between 5.5% and 8% [7] - The SHOP segment's same-store cash NOI is projected to grow between 11% and 16%, while the outpatient medical and research portfolio's same-store cash NOI is expected to be in the range of 2-3% [8]

Financial Performance & Portfolio Composition - The company's pro-rata annualized cash NOI totaled $413.912 million, with ISHC contributing 58.8%, OM 19.7%, SHOP 12.2%, Triple-Net Leased Properties 7.3%, and Debt Security Investment 2.0%[10] - Same-store ISHC revenues increased by 9.1% from Q4 2023 to $284.646 million in Q4 2024, and 7.8% from FY 2023 to $1.094 billion in FY 2024[15] - Same-store SHOP revenues increased by 11.5% from Q4 2023 to $44.793 million in Q4 2024, and 11.8% from FY 2023 to $174.310 million in FY 2024[26] - Same-store Triple-Net Leased Properties revenues increased by 1.0% from Q4 2023 to $7.597 million in Q4 2024, and 2.8% from FY 2023 to $30.583 million in FY 2024[31] Outpatient Medical (OM) - OM properties' ending occupancy was 87.9% as of December 31, 2024[20] - Same-store OM revenues increased by 2.1% from Q4 2023 to $31.960 million in Q4 2024, and 0.7% from FY 2023 to $127.722 million in FY 2024[20] Debt and Lease Expirations - Debt maturities and principal payments total $1.685 billion, with a weighted average interest rate of 4.42%[39] - In 2025, $14.576 million (13.4%) of OM ABR and $4.011 million (100%) of interest income are expiring[36] 2025 Guidance - The company anticipates total portfolio same-store NOI growth of 7.0% - 10.0% in FY 2025[45]